Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
We provide a chemotherapy treatment service that offers you both choice and flexibility. Chemotherapy is the use of cytotoxic (anti-cancer) drugs to destroy cancer cells in the body by disrupting the cancer cells and preventing them from growing and dividing.
Rutherford Innovations is going to use innovative technologies and research to improve outcomes for cancer patients within the UK and internationally
Led by our Chief Scientific Officer, Dr Ian Barwick, Rutherford Innovations is developing partnerships and collaborations with researchers and clinicians with the aim to confirm proton beam therapy as an accepted and cost-effective way to treat cancer alongside surgery, chemotherapy, conventional radiotherapy and immunotherapy.
Currently, Rutherford Innovations is sponsoring a major project with the University of Liverpool, to develop an innovative proton beam detector for improving the way the proton beam is measured and used, to treat patients and stems from the University’s links with the Large Hadron Collider at CERN in Switzerland. Rutherford Innovations is in discussion with a number of researchers, about providing access to proton beam time for research projects and would be pleased to discuss this facility with other research groups.
By working in collaboration with key strategic partners and industry leaders, such as Philips, Elekta, IBA and a number of UK universities, Rutherford Innovations will be able to advance research and future technologies in the oncology field.
Find out more
To find out more about Rutherford Innovations, or to discuss research collaboration opportunities, please contact Dr Ian Barwick, Chief Scientific Officer at: Ian.Barwick@therutherford.com
Rutherford Innovations Ltd, Celtic Springs, Spooner Close, Newport, South Wales, NP10 8FZ